259 related articles for article (PubMed ID: 35911730)
1. Combining Immune-Related Genes For Delineating the Extracellular Matrix and Predicting Hormone Therapy and Neoadjuvant Chemotherapy Benefits In Breast Cancer.
Liu J; Lei B; Yu X; Li Y; Deng Y; Yang G; Li Z; Liu T; Ye L
Front Immunol; 2022; 13():888339. PubMed ID: 35911730
[TBL] [Abstract][Full Text] [Related]
2. Transcriptome profiling of patient-derived tumor xenografts suggests novel extracellular matrix-related signatures for gastric cancer prognosis prediction.
Deng Z; Guo T; Bi J; Wang G; Hu Y; Du H; Zhou Y; Jia S; Xing X; Ji J
J Transl Med; 2023 Sep; 21(1):638. PubMed ID: 37726803
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial DNA methylation is a predictor of immunotherapy response and prognosis in breast cancer: scRNA-seq and bulk-seq data insights.
Ma Y; Du J; Chen M; Gao N; Wang S; Mi Z; Wei X; Zhao J
Front Immunol; 2023; 14():1219652. PubMed ID: 37457713
[TBL] [Abstract][Full Text] [Related]
4. A tumor microenvironment-related risk model for predicting the prognosis and tumor immunity of breast cancer patients.
Geng S; Fu Y; Fu S; Wu K
Front Immunol; 2022; 13():927565. PubMed ID: 36059555
[TBL] [Abstract][Full Text] [Related]
5. An Immune-Associated Genomic Signature Effectively Predicts Pathologic Complete Response to Neoadjuvant Paclitaxel and Anthracycline-Based Chemotherapy in Breast Cancer.
Fu C; Liu Y; Han X; Pan Y; Wang HQ; Wang H; Dai H; Yang W
Front Immunol; 2021; 12():704655. PubMed ID: 34526986
[TBL] [Abstract][Full Text] [Related]
6. Proposing a novel molecular subtyping scheme for predicting distant recurrence-free survival in breast cancer post-neoadjuvant chemotherapy with close correlation to metabolism and senescence.
Huang J; Zhang JL; Ang L; Li MC; Zhao M; Wang Y; Wu Q
Front Endocrinol (Lausanne); 2023; 14():1265520. PubMed ID: 37900131
[TBL] [Abstract][Full Text] [Related]
7. X-box binding protein 1 (XBP1): a potential role in chemotherapy response, clinical pathologic features, non-inflamed tumour microenvironment for breast cancer.
Zhu Z; Zhan H; Sun A; Huang H; Chen B; Zhang F
Biosci Rep; 2022 Jun; 42(6):. PubMed ID: 35543228
[TBL] [Abstract][Full Text] [Related]
8. Immunity and Extracellular Matrix Characteristics of Breast Cancer Subtypes Based on Identification by T Helper Cells Profiling.
Zhou Y; Tian Q; Gao H; Zhu L; Zhang Y; Zhang C; Yang J; Wang B
Front Immunol; 2022; 13():859581. PubMed ID: 35795662
[TBL] [Abstract][Full Text] [Related]
9. A Novel Immune and Stroma Related Prognostic Marker for Invasive Breast Cancer in Tumor Microenvironment: A TCGA Based Study.
Huang Y; Chen L; Tang Z; Min Y; Yu W; Yang G; Zhang L
Front Endocrinol (Lausanne); 2021; 12():774244. PubMed ID: 34867821
[TBL] [Abstract][Full Text] [Related]
10. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
11. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
12. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
[TBL] [Abstract][Full Text] [Related]
13. Baseline Mutations and Up-Regulation of PI3K-AKT Pathway Serve as Potential Indicators of Lack of Response to Neoadjuvant Chemotherapy in Stage II/III Breast Cancer.
Dong M; Shan B; Han X; Zhao X; Wang F; Zhu L; Ou Q; Ma X; Pan Y
Front Oncol; 2021; 11():784985. PubMed ID: 35480699
[TBL] [Abstract][Full Text] [Related]
14. Peripheral Blood Classical Monocytes and Plasma Interleukin 10 Are Associated to Neoadjuvant Chemotherapy Response in Breast Cancer Patients.
Valdés-Ferrada J; Muñoz-Durango N; Pérez-Sepulveda A; Muñiz S; Coronado-Arrázola I; Acevedo F; Soto JA; Bueno SM; Sánchez C; Kalergis AM
Front Immunol; 2020; 11():1413. PubMed ID: 32733470
[TBL] [Abstract][Full Text] [Related]
15. A Ribosome-Related Prognostic Signature of Breast Cancer Subtypes Based on Changes in Breast Cancer Patients' Immunological Activity.
Luan T; Song D; Liu J; Wei Y; Feng R; Wang X; Gan L; Wan J; Fang H; Li H; Gong X
Medicina (Kaunas); 2023 Feb; 59(3):. PubMed ID: 36984424
[No Abstract] [Full Text] [Related]
16. The regulatory roles of T helper cells in distinct extracellular matrix characterization in breast cancer.
Tian Q; Gao H; Ma Y; Zhu L; Zhou Y; Shen Y; Wang B
Front Immunol; 2022; 13():871742. PubMed ID: 36159822
[TBL] [Abstract][Full Text] [Related]
17. Identification of a pyroptosis-related prognostic signature in breast cancer.
Chen H; Luo H; Wang J; Li J; Jiang Y
BMC Cancer; 2022 Apr; 22(1):429. PubMed ID: 35443644
[TBL] [Abstract][Full Text] [Related]
18. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
19. Exploring the role of sphingolipid-related genes in clinical outcomes of breast cancer.
Pei S; Zhang P; Yang L; Kang Y; Chen H; Zhao S; Dai Y; Zheng M; Xia Y; Xie H
Front Immunol; 2023; 14():1116839. PubMed ID: 36860848
[TBL] [Abstract][Full Text] [Related]
20. A novel twelve-gene signature to predict neoadjuvant chemotherapy response and prognosis in breast cancer.
Wu J; Tian Y; Liu W; Zheng H; Xi Y; Yan Y; Hu Y; Liao B; Wang M; Tang P
Front Immunol; 2022; 13():1035667. PubMed ID: 36341435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
